Wen Hui Cai
Addiction Medicine · Tucson, AZNPI 1679657910
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $82,876 of the $110,643 with a category attached, or 74.9%. 26 manufacturers reported payments, led by AbbVie at 38.5% of the total. Reporting peaked in 2019 at $49,403 and has fallen 81.4% since, to $9,205 in 2025. Among addiction medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 520 payments — averaging $212.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$43K
- Teva Pharmaceuticals USA, Inc.$41K
- Alkermes, Inc.$14K
- Neurocrine Biosciences, Inc.$9K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$649
- plus $2K from 20 others
Across 22 payments — averaging $2699.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- H. Lundbeck A S$22K
- Teva Pharmaceuticals USA, Inc.$18K
- Alkermes, Inc.$11K
- Boehringer Ingelheim$5K
- Avanir Pharmaceuticals, Inc.$3K
What the payments were for
- Consulting fees$13,88813%
- Speaking & faculty fees$82,87675%
- Travel & lodging$4,2344%
- Food & beverage$9,4709%
- Education$1760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 182 | $42,588 |
| Teva Pharmaceuticals USA, Inc. | 70 | $41,044 |
| Alkermes, Inc. | 48 | $13,897 |
| Neurocrine Biosciences, Inc. | 28 | $9,218 |
| Johnson & Johnson | 44 | $1,056 |
| Otsuka America Pharmaceutical, Inc. | 33 | $649 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $478 |
| Vanda Pharmaceuticals Inc. | 15 | $323 |
| Sunovion Pharmaceuticals Inc. | 16 | $318 |
| Indivior Inc. | 9 | $186 |
| MDD US Operations, LLC | 7 | $105 |
| E.r. Squibb & Sons, L.L.C. | 4 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $77 |
| Axsome Therapeutics, Inc. | 3 | $68 |
| Janssen Scientific Affairs, LLC | 1 | $66 |
| Lundbeck LLC | 3 | $64 |
| Almatica Pharma LLC | 3 | $62 |
| USWM, LLC | 4 | $61 |
| Eisai Inc. | 3 | $59 |
| Shire North American Group Inc | 3 | $50 |
| Corium, LLC | 2 | $46 |
| Orexo US, Inc. | 3 | $41 |
| Biogen | 1 | $28 |
| Supernus Pharmaceuticals, Inc. | 1 | $28 |
| Braeburn Inc. | 1 | $20 |
| Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$110,643 in reported general payments places this provider in the 95th percentile of 37 addiction medicine providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $109,217 |
| CaplytaLumateperone Tosylate | 11 | $19,041 |
| RexultiBrexpiprazole | 11 | $16,865 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $12,791 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $4,098 |
| Duloxetine Hcl | 37 | $885 |
| Fluoxetine Hcl | 28 | $706 |
| Sertraline Hcl | 45 | $437 |
| Clonazepam | 23 | $431 |
| Lorazepam | 16 | $401 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 21 | $398 |
| Bupropion XlBupropion Hcl | 26 | $285 |
| Propranolol Hcl | 24 | $272 |
| Mirtazapine | 22 | $237 |
| Risperidone | 14 | $186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $9,218 | $109,21712 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $478 | $19,04111 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $649 | $16,86511 claims |
| Axsome Therapeutics, Inc.Auvelity | $68 | $12,79111 claims |
| Almatica Pharma LLCSertraline Hcl | $62 | $43745 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 37 addiction medicine providers in Arizona.
Other addiction medicine in Tucson
- Ernesto GarciaTucson$219
- Alaina MartinezTucson$171
- Christina BourneTucson$125
- Patty KaneTucson$100
- Leonard DitmansonTucson$34
- Wendell PhillipsPhoenix$16K
- Steven LocnikarScottsdale$7K
- Rosekamal McKinneyGlendale$5K
- Gerald HarrisPeoria$5K
- J Carvel JacksonMesa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.